, Volume 64, Issue 2, pp 431-432
Date: 20 May 2009

Anthocyanins-based drugs for colon cancer treatment: the nutritionist’s point of view

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

The recent review from Thomasset et al. [1] contributes to the very animated debate in progress in the scientific community regarding the anthocyanin (ACN) health benefits.

Evaluating the ACN future development as cancer drugs, the authors correctly tackle the issue of ACN bioavailability as a crucial point. However, some authors’ statements are questionable, particularly when they affirm that:

  1. “Protocatechuic acid…has recently been measured in human plasma at concentrations far in excess of the anthocyanin consumed”. In the work, they cite [2], it was reported that protocatechuic acid (PCA) is the main human metabolite of cyanidin-3-glucoside (CyG) following to administration of blood orange juice containing mainly cyanidin-3-glucoside and cyanidin-3-(6′-malonyl) glucoside among anthocyanins and no trace of PCA. Anyway measured PCA was never far in excess of the anthocyanin consumed, as it accounted for about 72% of ingested CyG: 44% dose in serum and 28% in the faeces.